💨 Abstract

Indian drug companies should not base their decisions on tariffs imposed by the U.S., according to Cipla's top executive. The industry is bracing for potential 25% tariffs on pharmaceutical imports by President Trump. Indian drugmakers are the top exporters of cheaper generic drugs to the U.S., but are awaiting clarity on the type and extent of tariffs. Most companies do not plan to relocate manufacturing to the U.S.

Courtesy: theprint.in

Summarized by Einstein Beta 🤖